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Nanotheranostics is an emerging field that aims to bring together nanoscale-engineered 
materials with biological systems to provide a combination of both therapeutic and diagnostic 
strategies. However, current theranostic nanoplatforms have serious limitations, mainly 
because there is often a mismatch between the physical properties of the selected nanomaterials 
and their ease of functionalization, loading ability or overall compatibility with bioactive 




nanocompartment clusters composed of two different types of polymersomes linked together 
by DNA. Careful design and procedure optimization allowed us to obtain clusters segregating 
human Dopa decarboxylase (DDC) as the therapeutic enzyme and fluorescent probes for the 
detection unit in distinct but colocalized nanocompartments. The diagnostic compartment 
provides a twofold function: firstly, trackability via dye-loading as the imaging component, and 
secondly, the ability to attach the cluster construct to the surface of cells expressing scavenger 
receptors. The therapeutic compartment, loaded with active DDC and permeabilized with outer 
membrane protein F (OmpF), triggers the cellular expression of a secreted embryonic alkaline 
phosphatase (SEAP) reporter enzyme via production of bioactive dopamine and activation of 
dopaminergic receptor D1 (DRD1), which is implicated in atherosclerosis. This dual-
functionality polymersome cluster architecture provides a novel type of two-compartment 
nanotheranostic platform that is expected to provide the basis of a new treatment strategy for 
atherosclerosis. This system is expected to expand versatility and diversify the types of 




Theranostic approaches provide improved medical solutions by associating therapy with 
diagnostics, thereby avoiding multi-step procedures and reducing delays in treatment, which 
may be particularly crucial in the case of rapidly evolving diseases. In particular, appropriately 
designed nanocarriers for nanotheranostics could offer advantages such as longer circulation 
time, passive accumulation in tumor sites due to the enhanced permeability and retention (EPR) 
effect, controllable release of the payload, and specific targeting by surface modification.[1–3] 
To date nanotheranostics are based on single-assembly architectures, containing both 




inorganic nanoparticles, polymeric micelles and soft nanocompartments (liposomes, 
polymersomes, layer-by-layer (LBL) capsules). The advantage of inorganic nanoparticles 
(quantum dots, superparamagnetic iron oxide nanoparticles (SPION), high-contrast gadolinium 
oxide (Gd2O3) nanoparticles, gold nanoparticles and gold nanorods) is that they intrinsically 
serve as imaging agents due to their specific properties, such as high luminescence, high 
contrast and localized surface plasmon resonance.[1] Stable small-molecular-weight drugs 
covalently bound to quantum dots and inorganic nanoparticles (doxorubicin (DOX),[5,6] 
camptothecin (CPT),[7,8] paclitaxel (PTX),[9] and palatinate[10]), as well as therapeutic proteins 
conjugated to the surface of nanoparticles,[11] or forming super-assemblies with 
nanoparticles,[12] have been introduced as theranostic systems. However, the use of inorganic 
nanoparticles for theranostic applications has limitations due to potential toxicity as a result of 
low clearance and accumulation.[13] Polymeric micelles have also been used for the 
development of nanotheranostics, mostly as carrier systems for both poorly soluble drugs and 
hydrophobic inorganic nanoparticles that can be co-encapsulated within their core.[14] However, 
their advantage of possessing a hydrophobic core is also a limitation, in that it allows the 
delivery of only hydrophobic payloads, which restricts the possible classes of deliverable 
compounds and thus the applications of this system.  
Soft nanocompartments (liposomes and polymersomes) are an appealing alternative for 
development of nanotheranostics because their architecture, consisting of an aqueous cavity 
surrounded by a layer with hydrophobic core, allows simultaneous loading of hydrophilic and 
hydrophobic molecules/nanostructures (small molecules, proteins, inorganic nanoparticles, 
DNAs, etc).[15–20] In particular, polymersomes based on amphiphilic block copolymers have 
advantages over lipidic compartments, such as increased mechanical stability and greater 




responsiveness, and programmability.[21,22] Polymersomes have been used both for co-delivery 
of drugs and imaging agents[23,24] and for development of catalytic compartments that mediate 
specific reactions inside the lumen.[25–27] For example, polymersomes loaded with enzymes and 
equipped with channel porins in the membrane were used for continuous production of 
antibiotics,[28] mimicking natural organelles by simultaneous degradation of reactive oxygen 
species and generation of a fluorescent product in vitro[29] and in vivo.[30] However, to our 
knowledge, theranostic polymersomes simultaneously bearing sensitive agents, such as 
degradable enzymes, along with imaging compounds have not been reported yet. As co-
encapsulation of sensitive enzymes with inorganic nanoparticles or other imaging agents can 
be detrimental to the enzyme, the use of only one compartment represents a drawback in 
development of efficient protein-based nanotheranostics.  
Super-assemblies are an alternative approach to co-encapsulation, as they consist of a 
combination of separate nanocompartments carrying complementary functions. To date, such 
super-assemblies have mostly been developed using inorganic nanoparticles,[31] such as gold 
nanorod dimers with NaGdF4 satellite nanoparticles for imaging-guided phototherapy
[32] and 
drug-encapsulated nanoparticles assembled into satellite structures with gold nanoparticles for 
chemothermal therapy and tumor imaging.[33] As most of the super-assemblies are held together 
by weak noncovalent interactions, they have the disadvantage of being vulnerable to 
dissociation, especially in long-term circulation and under complex physiological 
conditions.[34,35] Other super-assemblies based on micelles and soft nanocompartments have not 
yet been much explored, though their architecture might be more appropriate in terms of hosting 
sensitive molecules, such as enzymes, proteins, or RNA. 
Here, we introduce a theranostic strategy based on DNA-linked synthetic 




functionality- imaging and enzymatic activity- and interact specifically with cells (Figure 1). 
Polymersomes serve to protect the encapsulated compounds, especially sensitive ones like 
degradable enzymes, from harmful environmental factors, including proteolytic attack.[36] In 
our approach, DNA hybridization induces the formation of polymersome clusters that promote 
colocalization of separated local environments, allowing simultaneous encapsulation of 
molecules without sacrificing the encapsulation efficiency or the activity of the payloads. We 
previously reported that the size and architecture of DNA-linked polymersome clusters can be 
well controlled,[37] while single-stranded DNA (ssDNA) can be employed to attach them to 
scavenger receptor-expressing cells.[38] Here, we re-engineered such DNA-linked polymersome 
clusters by loading them with imaging and catalytic compounds to support theranostics. The 
therapeutic catalytic nanocompartments are loaded with the recombinant human enzyme Dopa 
decarboxylase (DDC), which converts L-Dopa to bioactive dopamine.[39] Dopamine is a key 
factor in atherosclerosis prevention,[40] regulating vascular dynamics by activation of 
dopaminergic receptor D1 (DRD1).[41–43] Atherosclerosis is characterized by plaque buildup in 
the arteries, restricting blood flow. It often has no symptoms until a life-threatening event such 
as a heart attack or stroke occurs, highlighting the need for early prevention and detection.[44] 
The imaging nanocompartment was paired with the therapeutic compartment, as the second 
component of the theranostic clusters, in order to provide a sensitive detection method for 
atherosclerotic lesions by attaching to inflammatory cells recruited to these locations.[45,46] In 
order to prototype and monitor the properties of the imaging compartment, we chose a 
fluorescent dye (DY-633) to model the encapsulation of small hydrophilic imaging agents 
within polymersomes. 
The potency of the theranostic clusters was evaluated with the cell line HEKREWARD, 




able to respond to dopamine enzymatically produced in the catalytic nanocompartment. The 
therapeutic activity of the DNA-linked polymersome clusters was determined by evaluating the 
concentration of the reporter, human secreted embryonic alkaline phosphatase (SEAP), 
produced by HEKREWARD cells in the presence of dopamine, while their imaging function was 
established by visualizing their localization and interaction with the cell surface. 
The unique advantage of our DNA-linked polymersome clusters over other currently 
available theranostic systems resides in the segregated location of the imaging and catalytic 
compounds, which allows them to act independently, without interference that might 
compromise their specific functionality. As our strategy is based on a modular design, it should 
be straightforward to expand it from the example presented here to a variety of other medical 
applications, simply by changing the functional components within the segregated 
compartments, and then zipping them together in clusters.  
 
2. Results and Discussion  
 
2.1. Design of theranostic polymersome clusters 
 
2.1.1. Development strategy of DNA-linked nanocompartment clusters  
 
Theranostic clusters are formed by self-organization of two types of nanocompartments: the 
therapeutic polymeric compartment that contains the catalytically active species, and the 
imaging polymeric compartment that allows the detection and tracking of the whole clusters 
(Figure 1). DNA hybridization was used as the driving force to control the construction of 
nanocompartment clusters with sub-micrometer size.[37] The therapeutic compartment was 
functionalized with one type of ssDNA (ssDNAa), while the imaging compartment bears the 




order to modulate the DNA attachment to the polymersomes, we also used variants of these 
ssDNA sequences (called spacer-ssDNAa and spacer-ssDNAb), which contain an additional 
noncomplementary DNA linker acting as a spacer between the surface of the polymersomes 
and the complementary DNA sequence. We compared clusters made with spacer-ssDNA and 
clusters hybridized with ssDNA, in order to select the most suitable approach to support 
efficient theranostic application.  
We selected amphiphilic diblock copolymers poly(dimethylsiloxane)-block-poly(2-
methyloxazoline), PDMS-PMOXA for formation of the nanocompartments, because 
copolymers with a PDMS hydrophobic domain and a PMOXA hydrophilic domain generate 
polymersomes with flexible membranes,[48] increased mechanical stability and low toxicity, 
both in vitro and in vivo.[30] Azide-functionalized poly(dimethylsiloxane)22-block-poly(2-
methyloxazoline)8 (PDMS22-PMOXA8-OEG3-N3) (Figure S1) was used to form polymersomes 
with exposed azide functional groups that do not interfere with other biological processes, as 
they are bio-orthogonal[49] and promote the attachment of ssDNA. Conjugation was carried out 
through azide–alkyne cycloaddition (SPAAC) between dibenzocyclooctyne (DBCO) 
covalently attached to the ssDNA and the azide moieties on the diblock copolymers.[37] We 
specifically selected short polymer blocks to generate nanocompartments with thin but stable 
membranes, in order to permit functional insertion of membrane proteins to support the in situ 
enzymatic reaction of the catalytic nanocompartment.[48] Importantly, low-molecular-weight 
PDMS22-PMOXA8 block copolymer is expected to self-assemble rapidly into vesicles, 
shortening the process of polymersome formation. Indeed, our PDMS22-PMOXA8-OEG3-N3 is 
particularly efficient as it self-assemble into vesicles in less than 1 min when rehydrated in PBS 
at room temperature (Figure S2). The vesicular structure of the obtained self-assembled 




(TEM), dynamic light scattering (DLS) and static light scattering (SLS) (Figure S2). The size 
of the polymersomes was 175 ± 88 nm, and the Rg/Rh ratio of the hydrodynamic radius (Rh) to 
the radius of gyration (Rg) was 0.96, indicating a hollow spherical architecture. This ease of 
formation of polymersomes, combined with the swiftness of PDMS22-PMOXA8-OEG3-N3 
copolymer formation, also enabled us to increase the initial concentration of copolymer to 10 
mg/mL, resulting in a high number of polymersomes (1.3*1012 vesicles/mL as determined by 
nanoparticle tracking analysis). 
Our strategy to obtain DNA-linked polymersome clusters for theranostics is modular, 
being based on three steps: i) the formation of imaging nanocompartments, ii) the formation of 
catalytic nanocompartments able to produce a specific therapeutic compound, and iii) the 
functionalization of each type of nanocompartment with ssDNA and complementary ssDNA to 
induce self-organization leading to the formation of nanotheranostic clusters. This design 
strategy based on segregated locations of the therapeutic and imaging compounds allows the 
flexible control of each component in terms of type of payload and associated properties. The 
final cluster, coupling both nanocompartments, enables control and tracking of the bio-location 
of the nanotheranostic platform, as well as delivering the desired cell response.  
 
2.1.2. Formation of the imaging nanocompartment 
 
The imaging nanocompartment (Dye-Ncomp) consists of a polymersome loaded with 
fluorescent dye. We chose to encapsulate DY-633 into polymersomes as a model of the 
entrapment of small imaging probes in the cavity of the nanocompartments. Like most of the 
small hydrophilic molecules that have been used to develop imaging nanocompartments, DY-




temperature, overnight stirring) by self-assembly through film rehydration of the PDMS22-
PMOXA8-OEG3-N3 polymer (Figure 2A). The resulting imaging nanocompartments have a 
hydrodynamic diameter DH of 218 ± 86 nm as measured by dynamic light scattering (DLS), 
and their spherical shape was confirmed by transmission electron microscopy (TEM) (Figure 
S3A). As expected, encapsulation of the dye did not affect the self-assembly process, and the 
resultant imaging nanocompartments appeared similar to empty ones (Figure S3B). Based on 
these results with DY-633, the incorporation of other imaging components consisting of stable 
small hydrophilic molecules should be relatively straightforward. In contrast, the development 
of therapeutic catalytic compartments is more complex, as it involves active enzymes. 
 
2.1.3. Formation of the catalytic nanocompartment with a therapeutic role 
 
The catalytic nanocompartment (DDC-Ncomp) consists of human DDC encapsulated in the 
inner cavity of polymersomes equipped with a channel porin, which supports in situ enzymatic 
reactions by allowing the passage of substrates and products through the polymeric membrane 
(Figure 2B). Compared to other therapeutic nanocompartments reported for theranostic 
applications, which are based on the entrapment of small and stable therapeutic compounds,[1] 
we aimed to develop a more versatile and dynamic system involving an active enzyme that 
produces the desired drug inside the therapeutic compartment. By incorporating an active 
enzyme, we can produce the needed therapeutic compound on demand at selected locations 
rather than having a simple one-time delivery system. But, like many enzymes carrying out 
physiological functions in the human body, DDC is vulnerable to degradation, and loses its 
activity significantly at 37 °C.[50] 
Therefore, the formation of DDC-Ncomp requires a complex preparation methodology based 




inside polymersomes. To preserve DDC activity, it was crucial to conduct polymersome 
formation as quickly as possible by shortening the time of film rehydration, since at least one 
day is generally required for the self-assembly of most amphiphilic block copolymers with high 
molecular weight.[29,51] Our short PDMS22-PMOXA8-OEG3-N3 copolymer favoured the 
formation of polymersomes in less than 1 min, thus supporting a rapid generation of DDC-
Ncomps (see above). It was also essential to permeabilize the polymeric membrane of PDMS-
PMOXA polymersomes to support enzymatic activity by implementing small-molecular flow 
through the nanocompartment. We chose the channel porin OmpF as a biological tool for 
permabilization, as it can be inserted in the membrane of PDMS-PMOXA polymersomes and 
has a molecular weight cutoff of 600 Da,[52] thus allowing the passage of small molecules such 
as the DDC substrate L-Dopa and product dopamine. To investigate the possibility of rapid 
insertion of OmpF during the prompt formation of polymersomes via film rehydration, we 
encapsulated horseradish peroxidase (HRP) as a model enzyme that is more stable and easier 
to work with than DDC. Rehydration solution containing HRP and different concentrations of 
OmpF (0.02 mg/mL and 0.04 mg/mL) in PBS was used to form HRP-loaded polymersomes 
with OmpF inserted in the polymeric membrane. As encapsulated HRP catalyses the formation 
of fluorescent resorufin, a detectable fluorescence signal is only obtained in presence of HRP 
substrate (Amplex red) when the polymeric membrane is permabilized, demonstrating the 
proper insertion of OmpF (Figure S4A).[53] Production of resorufin was recorded directly after 
the addition of Amplex red to a solution of HRP-loaded polymersomes formed in presence of 
OmpF, while no fluorescence was observed when polymersomes were formed without OmpF 
(Figure S4B). This demonstrates the functional insertion of OmpF during the rapid formation 
of polymersomes via film rehydration (Figure S4C), and highlights the ease with which 




thinness of the membrane.[48] The extremely rapid polymersome formation (less than 1 min) 
and simultaneous permeabilization by OmpF insertion during the self-assembly process support 
our approach to speed polymersomes production in order to minimize the loss of sensitive 
enzyme (DDC in this case) from the catalytic compartment.  
Following these preliminary optimizations using PBS and model enzyme HRP, we 
proceeded with the encapsulation of our biologically relevant enzyme DDC and optimized the 
conditions of self-assembly (composition of the rehydration solution, temperature and time). 
To prevent the degradation of DDC in solution during film rehydration, we added bovine serum 
albumin (BSA), a commonly used protein stabilizer.[54] We also reconstituted DDC holoenzyme 
by adding its cofactor pyridoxal phosphate in the rehydration solution. The association of DDC 
apoenzyme with its cofactor generates the holoenzyme, which is less solvent-accessible, and 
thus more stable and more compact.[55] As a result, the rehydration solution used to form DDC-
Ncomp contained DDC holoenzyme, remaining unbound cofactor pyridoxal phosphate, BSA 
and OmpF. The obtained DDC-Ncomp formed by rapid film rehydration at room temperature 
was a mixture of vesicles and worms (Figure S51), probably due to the presence of a large 
number of molecules in the solution, slowing down self-assembly.[56] A rehydration time of 2 
h was necessary to obtain only vesicular-shaped DDC-Ncomp at room temperature (Figure 
S5B).  
To avoid the exposure of DDC to room temperature for 2 h, which can decrease its 
activity, we investigated the possibility of forming DDC-Ncomp at low temperature (4 °C). 
After 2 h of rehydration at 4 °C, we obtained a mixture of polymersomes and worms (Figure 
S5C), presumably due to the slower kinetics of self-assembly at this temperature.[56] An 
extended rehydration time of 3 h was necessary to obtain only vesicular–shaped DDC-Ncomp 




and BSA in the lumen did not influence the polymersome structure, as judged from TEM 
micrographs, or the size of DDC-Ncomp, since DH remained constant (184 ± 66 nm) as 
determined by DLS (Figure S5D). Systematic investigation of factors affecting the self-
assembly process and the enzyme activity (molecular properties of the copolymers and 
polymersome membrane, self-assembly conditions, stabilizer protein, reconstitution of 
holoenzyme) led to an optimized procedure to prepare catalytic compartments containing 
sensitive enzymes, such as DDC-Ncomp (Figure 2A). 
 
2.1.3. ssDNA functionalization of polymersomes and clustering of both types of 
nanocompartments for theranostics 
 
With both imaging and therapeutic nanocompartments in hand, the next step consisted of 
functionalization with ssDNA to assemble them into theranostic clusters. Here again, different 
strategies had to be adopted to preserve DDC activity during the ssDNA functionalization of 
DDC-Ncomp and subsequent formation of clusters. The usage of PDMS22-PMOXA8-OEG3-N3 
copolymer, consisting of short polymer chains less entangled inside the polymersome 
membrane, promoted the coupling of the ssDNA by increasing the exposure of the azide 
terminal groups. We used 100 % of this azide-functionalized polymer to obtain the highest 
density of azide at the surface of polymersomes, thus enabling the attachment of a maximal 
number of ssDNAs. In addition, we investigated the influence of an additional spacer on the 
ssDNA sequence in facilitating the formation of dsDNA by hybridization, and thus the 
clustering of the complementary ssDNA-functionalized polymersomes.  
Dye-Ncomp is inherently stable, so its functionalization with ssDNAb or spacer-




reaction efficiency. To quantify the number of ssDNAb attached per polymersome, ssDNAb 
labelled with a fluorescent dye (Atto-488) were used to enable detection using fluorescence 
correlation microscopy (FCS). We confirmed that fluorescently labelled ssDNAb (without 
DBCO) did not interact with polymersomes, so that the count per molecule obtained for 
ssDNAb-functionalized Dye-Ncomp reflected only covalently attached ssDNA (Figure S6A) 
and did not affect the structure of polymersomes (Figure S6B). The number of ssDNAb attached 
per Dye-Ncomp can be determined by dividing the counts per molecule of ssDNAb-
functionalized polymersomes by the counts per molecule of free ssDNAb (Figure S6C). We 
obtained an average value of 163 ± 61 of ssDNAb per Dye-Ncomp (Figure 2C). Similarly, we 
determined the density of spacer-ssDNAb as 196 ± 96 spacer-ssDNAb per Dye-Ncomp (Figure 
2C, Figure S7). 
In order to avoid loss of the catalytic activity of DDC while performing ssDNA 
functionalization of DDC-Ncomp, we again had to optimize the reaction conditions. As 
described for DDC-Ncomp formation, we first investigated the feasibility of conducting ssDNA 
conjugation at 4 °C by using empty polymersomes (rehydrated with PBS only). DY-633-
labelled ssDNAa and spacer-DNAa were used to assess the number of ssDNA covalently 
attached to polymersomes at 4°C during overnight reaction (Figure S7A). The attachment of 
ssDNAa and spacer-ssDNAa to empty polymersomes was achievable under these conditions 
(Figure S7B), but the efficiency of the reaction was drastically reduced compared to the 
conjugation reactions at 37 °C. Under these conditions (4 °C, overnight) for functionalization 
of DDC-Ncomp, we obtained an average number of 23 ± 6 for ssDNAa and 22 ± 6 for spacer-
ssDNAa attached per polymersome (Figure 2C). Note that ssDNA functionalization of the 
nanocompartments did not affect the architecture of the vesicles or their size, as determined by 




present at the surface of DDC-Ncomp should be counterbalanced by the large amount of 
complementary ssDNAb attached to the Dye-Ncomp, allowing the effective formation of 
theranostic clusters. 
We investigated the cluster formation between DDC-Ncomp and Dye-Ncomp under 
mild conditions at 20 °C. We compared the clusters formed using polymersomes functionalized 
with ssDNA and those formed using spacer-ssDNA. After overnight incubation at 20 °C, no 
clusters were observed in the case of ssDNA-functionalized polymersomes (Figure 2G). In 
contrast, theranostic clusters formed rapidly when spacer-ssDNA was used. These results 
support the idea that the spacer enhances the exposure of the complementary ssDNA sequences 
at the surface of polymersomes, resulting in easier hybridization of complementary strands to 
trigger the formation of clusters.[37,38] The theranostic clusters formed using spacer-ssDNA 
rapidly self-organized into sub-micrometer-sized structures that further aggregated after 4 h 
(Figure 2G). To slow the ssDNA hybridization process, so that the cluster size could be 
restricted, as well as to minimize loss of DDC activity, we investigated the formation of clusters 
at 4°C using spacer-ssDNA. But, as no clusters were formed after overnight incubation at 4°C 
(Figure S9), we decided to control the size of the clusters by shortening the clustering time to 
20 min at 20°C; this afforded theranostic clusters of around 500 nm in size (Figure 2H, Figure 
2I). These clusters were stored at 4 °C or used immediately. The different strategy adopted to 
obtain a high density of ssDNAb per Dye-Ncomp enabled us to compensate for the low 
incorporation of ssDNAa per DDC-Ncomp obtained at the low temperature. Overall, the results 
indicate that incorporation of a spacer within the ssDNA facilitates the hybridization of ssDNA 
and promotes the formation of nanotheranostic polymersome clusters. 
 





2.2.1. Kinetic assay for the detection of DDC-triggered production of dopamine 
 
We first estimated the DDC encapsulation efficiency in polymersomes using the model protein 
BSA, because of its similarity to DDC in size, molecular weight, and solubility (PDB ID: 3V03 
and 3RBL); it is also an established model protein for UV-vis absorption measurements[57–59] 
(see Materials and Methods for further details). We obtained a value of 23.01 ± 6.03 DDC 
molecules per polymersome, representing an encapsulation efficiency of 15.6 ± 4.12 %, which 
is consistent with the range of encapsulation efficiencies generally obtained for enzymes within 
PDMS-PMOXA polymersomes.[53] This provides a concentration of encapsulated DDC of 
0.054 µg/mL for DDC-Ncomp and the corresponding clusters. 
Having determined the amount of encapsulated DDC per polymersome, we proceeded 
to assess the production rate of dopamine via irreversible decarboxylation of the substrate L-
Dopa under physiological conditions.[60] The production of dopamine by DDC was carried out 
for up to 24 h in PBS at 37 °C; however, both L-Dopa and dopamine spontaneously auto-oxidize 
in vivo,[61] and this also occurs in PBS, affording a dark, insoluble polydopamine precipitate.[62] 
To overcome this problem, we decided to add a reducing agent during the DDC-triggered 
conversion reaction of L-Dopa to dopamine in PBS. We chose glutathione, the most abundant 
free thiol in mammalian cells, and a major antioxidant in the brain, where it is implicated in the 
prevention of L-Dopa and dopamine oxidation.[63,64] As expected, no dark precipitate was 
formed in the presence of glutathione (Figure S10). The assessment of dopamine production by 
DDC was then possible by HPLC (Figure S11), allowing us to calculate the percent conversion 
of L-Dopa to dopamine based on the areas under the corresponding peaks (Figure 3A). It should 
be noted that the percentages of conversion recorded all correspond to dopamine production in 





2.2.2. Activity of the therapeutic nanocompartment in situ 
 
Free (non encapsulated) DDC was first assessed to verify the role of BSA as a stabilizer. We 
compared solutions of free DDC containing only DDC diluted in PBS and containing DDC in 
the presence of 0.1 wt% BSA, corresponding to the BSA concentration used in the rehydration 
solution to form DDC-Ncomp (Figure 3B, grey and black bars respectively). At all measured 
time points, the percent conversion of L-Dopa to dopamine in the presence of BSA was higher 
than in the case of the free DDC alone, confirming that BSA stabilizes DDC. 
Considering that the amount of Dopamine produced is closely related to the enzyme 
concentrations (Figure S12), to compare the activity of free DCC with that of encapsulated 
DDC inside DDC-Ncomp, as well as DDC-Ncomp clusters, we ensured that DDC was 
contained at the same concentration (0.05 µg/mL) in all samples. As shown in Figure 3, control 
DDC-Ncomp without OmpF did not show any conversion of L-Dopa since the polymersome 
membrane is impermeable (Figure 3B, purple bars). Production of dopamine was observed 
when DDC was encapsulated in OmpF-equipped DDC-Ncomp, ssDNA functionalized DDC-
Ncomp and DDC-Ncomp clusters with the imaging compartment (forming the nanotheranostic 
system). These results confirm the encapsulation of active DDC inside polymersomes, and the 
ability of the system to transport and convert L-Dopa and to release therapeutic dopamine 
(Figure 3B, orange blue and green bars). The percent conversion of L-Dopa to dopamine by 
encapsulated DDC is  lower than that of free DDC in presence of BSA, presumably due to slow 
diffusion through the channel porin, resulting in a slower reaction in situ. The attachment of 
ssDNAa and subsequent clustering of DDC-Ncomp together with Dye-Ncomp also decreases 
the efficacy of conversion of L-Dopa to dopamine (Figure 3B, blue and green bars). This 




the ssDNA and ssDNAa-ssDNAb bridges formed during the polymersome clustering process. 
Although the DDC-Ncomp-based reporter gene assay is orders of magnitude more sensitive 
than an HPLC-based system, it is clear that the amount of dopamine (µM) produced by the 
DNA-linked theragnostic polymersome clusters is within the range required to induce a cellular 
response (Figure S13). With regards to the reaction kinetics at physiological temperature 
(37 °C), we compared the conversion of L-Dopa to dopamine by free and encapsulated DDC at 
the beginning of the reaction (up to 2 h) and after 24 h (Figure 3B). Considering that the L-
Dopa substrate is present in excess, the slower conversion rate observed after 24 h is not 
attributable to a decrease in substrate availability, but should reflect deactivation of the enzyme. 
 
2.2.3. Stability of the therapeutic nanocompartment to thermal deactivation 
 
To gain insight into the thermal stability of DDC, we stored free and encapsulated DDC 
enzyme at 37 °C for different periods of time (0 to 2 h) prior to the addition of L-Dopa, and 
then measured dopamine production after 24 h (Figure 3C). Almost no dopamine was produced 
when free or encapsulated DDC was stored at 37 °C for 2 hours before addition to L-Dopa. 
These results confirm the rapid thermal inactivation of DDC at 37 °C, and support our 
explanation of the slower rate of dopamine formation after a longer reaction time at 37°C. To 
evaluate the stability of free and encapsulated DDC upon storage at a lower temperature, we 
repeated the same experiment at 4 °C (Figure 3D). The encapsulated DDC maintained a 
reasonably consistent percent conversion of dopamine up to one week, while free DDC showed 
a more pronounced decrease in dopamine formation (9.1% loss of dopamine production for free 
DDC with BSA, compared to 3.5% loss for DDC-Ncomp after 7 days). This behavior can be 




findings.[65] Since no activity of encapsulated DDC was retained at 37 °C, we hypothesized that 
DDC is so sensitive to thermal denaturation that the stabilizing effect of polymersomes is only 
observable at low temperatures. Thus, even though polymersomes do not extend the active 
period of encapsulated DDC in PBS at 37°C, they still enhance the stability at 4°C, which may 
permit longer-term storage – a desirable feature for translational applications.  
 
2.3. Cell response induced by the therapeutic compartment and theragnostic clusters 
 
To investigate the ability of our therapeutic compartment and the theragnostic system of DNA-
linked polymersome clusters to produce dopamine in vitro, we monitored the response of 
dopamine-sensing cells during incubation in the presence of DDC-Ncomp and corresponding 
DNA-linked polymersome clusters. We selected the HEKREWARD double-transgenic cell line as 
a dopamine-sensing platform; it was previously used to investigate the reward-based control of 
hypertension via a synthetic brain-dopamine interface.[47] These cells were engineered to 
ectopically express human dopamine receptor 1 (DRD1), enabling dopamine-triggered 
production of the reporter, SEAP. SEAP is induced whenever the cells are exposed to 
dopamine; other metabolically related small molecules, such as L-Dopa, did not trigger DRD1-
driven SEAP expression. This HEKREWARD cell line is sensitive to dopamine in the nanomolar 
range, positioning it as a very sensitive and selective dopamine sensor. It has also been reported 
that the cellular expression of SEAP was the highest when the cells were incubated with 
dopamine for 3 days.[47] The delay presumably reflects the fact that the response to dopamine 
requires time for the cells to initiate the pathways required for SEAP expression. Therefore we 
chose an incubation time of 3 days for incubation of the DDC-Ncomp and theragnostic 




activity after 2 hours at physiological temperature in PBS, the production of dopamine reaches 
a concentration 31 µM, which is high enough to induce a relevant cell response.  
We first investigated the response of HEKREWARD cells when incubated with dopamine 
alone at various concentrations for 3 days. We observed a linear dependence of cellular 
expression of SEAP upon dopamine concentration up to 1 µM (Figure S13). No further increase 
in SEAP expression was observed at higher concentrations of dopamine, and 12 U/L of SEAP 
was the highest cellular response achieved in our experiments (Figure S13). Second, we 
investigated the cellular response to dopamine produced by free DDC (Figure 4A). The 
maximum level of SEAP produced was 3 U/L (Figure 4B), probably due to the rapid 
deactivation of DDC as a result of the cumulative effects of physiological temperature and the 
cellular milieu. In these cellular assays, no change in SEAP production was observed with free 
DDC in presence of BSA (Figure 4B) or in PBS buffer only (Figure S14). This lack of a 
stabilizing effect of BSA on DDC in cell assays could be explained by enhanced sensitivity of 
DDC under cellular conditions, as well as a dilution effect of BSA with other proteins. 
Interestingly, we observed higher levels of SEAP production in the presence of DDC-
Ncomp in comparison with free DDC (Figure 4C). Our results clearly indicate the protective 
role of polymersomes in shielding DDC from attack in the cellular environment (Figure 4C). 
Within the nanocompartments, BSA can continue to stabilize DDC. DDC-Ncomp 
functionalized with ssDNAa, and also when present as therapeutic nanocompartments in the 
DNA-linked theragnostic clusters, successfully induced a cellular response, of the same order 
of magnitude as DDC-Ncomp (Figure 4D, Figure S15). Notably, in the cell-based assay, the 
presence of ssDNAa and the location of DDC-Ncomp in theragnostic clusters appears to 
compensate for the reduced activity observed in PBS, in agreement with other studies showing 




free enzymes.[53] This effect is most likely due to the shielding of polymersomes and to the 
presence of ssDNAa on the surface of the polymersomes, promoting the attachment of single 
polymersomes and DNA-zipped polymersome clusters to the cell membrane.[62] This point will 
be discussed in more detail in the following section. Such proximity with the cell membrane 
eventually leads to a locally increased concentration of dopamine near the DRD1 receptors, 
resulting in an increase of SEAP expression.  
 
2.4. Tracking the behavior of polymersome clusters in the presence of cells via the 
imaging compartment 
 
We previously showed that DNA-zipped clusters possess interesting surface-binding ability to 
epithelial cells due to their physical properties.[38] Their softness, increased size (unfavourable 
for endocytosis), and availability of ssDNA on the surface promote their attachment to 
scavenger receptors present at the surface of epithelial cells. Scavenger receptors are known to 
bind DNA, RNA and other negatively charged large molecules.[66] Zeta potential measurements 
of our nanocompartments confirmed that ssDNA-functionalized polymersomes were more 
negatively charged (- 13.53 ± 2.54 mV for Dye-Ncomp and - 6. 93 ± 3.38 mV for DDC-Ncomp) 
than non ssDNA-functionalized polymersomes (- 5.24 ± 0.4 mV), thus making them prime 
candidates for attachment to scavenger receptors. Since the HEKREWARD cell line used for our 
experiments is of epithelial origin, it should interact with ssDNA-functionalized polymersomes 
and clusters. To investigate the interaction between the DNA-linked polymersome clusters and 
this new engineered HEKREWARD cell line, we used ssDNA-functionalized polymersomes or 
DNA-linked polymersome clusters loaded with fluorescent dyes (DY-633 and Atto-488) as 
imaging compartments. The binding efficiency of spacer-ssDNA-bearing single polymersomes 




concentrations as used for the cellular assay. As expected, the single imaging compartments 
functionalized with spacer-ssDNA bound to the cell surface of HEKREWARD, whereas non-
functionalized polymersomes showed lower attachment (Figure S16). To investigate whether 
the clusters also bind to the cell surface, as was the case for the functionalized polymersomes, 
we loaded the therapeutic compartment with Atto-488 for visualization purposes and kept the 
imaging compartment loaded with DY-633 as described above (Figure 5). We incubated these 
dye-loaded clusters in the presence of the cells for 24 hours, then washed and imaged the cells 
to assess not only binding to the cell surface, but also whether or not the clusters maintain their 
bound conformation. For the theranostic system to function, it is imperative that the clustered 
architecture is maintained and that the two compartments coexist, functioning in unison. After 
incubation with the cells and rigorous washing, we could indeed observe the colocalization of 
the Atto-488 and DY-633 compartments, with a Pearson’s colocalization coefficient of 0.77 ± 
0.09. The co-localisation observed for the two different compartments of the clusters 
demonstrates clustering of the nanocompartments and the stability of the DNA linkers in vitro 
(Figure S17). Considering the sensitivity and low lifetime of DDC, we wanted to determine 
how fast cell binding of the clusters occurs, as this would determine the overall efficacy of our 
system. For this experiment, we incubated the cells in the presence of the dye-loaded clusters 
and observed their attachment via CLSM live imaging. The results indicate that the cell binding 
process is fast, as fluorescence was apparent at the cell membrane within 10 min, and continued 
to increase thereafter (Figure S18). The fast binding of the DNA-linked polymersome clusters 
to the cell surface, before thermal deactivation of DDC can occur, is what leads to the locally 
enhanced production of dopamine, thus resulting in higher SEAP production as compared to 




of the dye-Ncomp to track itself and polymersome clusters over time in a biologically relevant 




Here we engineered a novel platform composed of segregated catalytic and imaging polymeric 
compartments linked together via DNA hybridization to form a modular nanotheranostic 
system. A combination of optimized construction strategies, i.e., 1) high polymer concentration, 
2) short block-copolymers, 3) short rehydration time, and 4) low temperature, coupled with 
mild encapsulation conditions, permits the effective loading of DDC in the lumen of 
polymersomes, affording the active therapeutic compartment (DDC-Ncomp) that is able to 
produce dopamine in PBS and cell media. The surface functionalization of DDC-Ncomp with 
DNA was also successfully achieved under mild conditions where DDC was not substantially 
degraded, even though the amount of DNA attached was relatively low. The polymersomes 
protect DDC activity sufficiently during storage at 4 °C and also in cell media. As a result, 
active polymersomes encapsulating DCC and corresponding clusters are able to trigger a 
cellular response via dopamine production and activation of dopamine receptors, and the 
response is considerably enhanced compared to the case of free DDC. By employing a modular 
system, we were able to assemble the imaging compartment (Dye-Ncomp) under harsher 
conditions that permitted a high encapsulation efficiency of the stable DY-633 dye and an 
increase in amount of attached DNA on the polymersome surface, compared to DDC-Ncomp. 
This enabled the successful formation of theranostic clusters via DNA-zipping. The presence 
of DNA on the surface of DDC-Ncomp affects the dopamine production rate by hindering the 
passage of substrate through the OmpF pore, but interestingly, in cell experiments, this DNA-




production of dopamine in close proximity to the dopamine D1 receptor. DNA promotes the 
attachment of polymersomes and clusters at the surface of epithelial cells, leading to an 
increased local concentration of dopamine at the cell surface, followed by efficient receptor 
activation. From a therapeutic point of view, dopamine activation of cell-surface dopamine D1 
receptor molecules present on peripheral arteries has been shown to prevent atherosclerosis.[41–
43] Secondly, atherosclerosis can be regarded as a chronic inflammatory state that involves the 
presence of scavenger receptor-expressing macrophages in locations where atherosclerotic 
lesions are formed.[45,67] By attaching the nanotheranostic clusters to these macrophages, we 
may be able to detect the early stages of artherosclerotic plaque formation as well as generate 
dopamine, preventing progression of the disease. Most current treatments and detection 
methods for atherosclerosis are invasive and inadequate[68] and therefore an early detection and 
prevention system such as our nanotheranostic platform could provide a much-needed 
alternative. Further, since our system is modular, it should be possible to extend its applicability 
to other disease states. 
 
 
4. Experimental Section  
 
Materials: DBCO-ss-DNA sequences were purchased from IBA Lifesciences (Göttingen, 
Germany). DDC was purchased from Biotechne (Zug, Switwerland). Dulbecco’s PBS was 
purchased from BioConcept (Allschwill, Switzerland). L-Dopa (levodopa), dopamine 
hydrochloride, pyridoxal 5’-phosphate monohydrate, BSA, reduced L-glutathione, 
diethanolamine, L-homoarginine, magnesium chloride, and p-nitrophenyl phosphate were 
obtained from Sigma-Aldrich (St. Louis, USA). N-Octyl-β-D-glucoside was purchased from 




ATTO-TEC GmbH (Siegen, Germany) and Dyomics GmbH (Jena, Germany), respectively. All 
compounds and solvents were used as received.  
 
Synthesis of PDMS22-PMOXA8-OEG3-N3: PDMS22-PMOXA8 with a hydroxyl functional group 
(PDMS22-PMOXA8-OH) was synthesized accordingly to the well-established protocol of our 
research group.[69] PDMS22-PMOXA8 with azide as the end functional group (PDMS22-
PMOXA8-N3) was synthesized accordingly our recently published procedure
[37] with slight 
modifications. Briefly, PDMS22-PMOXA8-OH (350 mg) was first dissolved in 10 mL 
anhydrous chloroform at RT, then succinic anhydride (30 mg,), 4-dimethylaminopyridine (5 
mg) and TEA (30 μL) were added successively. The mixture was deoxygenated by means of 
three vacuum-argon cycles, and then stirred for another 72 h at room temperature under Ar. 
Ultrafiltration afforded colorless PDMS22-PMOXA8 with a carboxylic acid end group 
(PDMS22-PMOXA8-COOH) (yield: 300 mg, 86%). This PDMS22-PMOXA8-COOH (300 mg) 
was dissolved in anhydrous chloroform at room temperature, then 11-azido-3,6,9-
trioxaundecan-1-amine (50 mg), N,N'-dicyclohexylcarbodiimide (46 mg) and 4-
dimethylaminopyridine (3 mg) were added to the solution. The mixture was deoxygenated three 
times, then stirred at 30 rpm for another 48 h at RT. Ultrafiltration afforded colorless PDMS22-
PMOXA8-N3 (yield: 220 mg, 73%). 
 
Rapid formation of PDMS22-PMOXA8-OEG3-N3 polymersomes: PDMS22-PMOXA8-OEG3-N3 
block copolymers were dissolved in ethanol to yield a stock solution with a concentration of 10 
mg/mL. 400 µL of this solution was transferred into a 5 mL round-bottomed flask, and dried in 
a rotary evaporator (170 mbar, 40 ˚C, 75 rpm). 1 mL of PBS was added to the residue, and the 




extruded 15 times through a polycarbonate (PC) membrane with a 200 nm diameter pore size 
on an Avanti mini-extruder (Avanti Polar Lipids, Alabama, USA) to unify the size of the 
polymersomes. 
 
Conjugation of DNA with empty polymersomes: Empty polymersomes (4 mg/mL) were mixed 
with 1 eq. per azide group of ssDNAa or spacer-ssDNAa labelled with DY-633 (0.5 mM in 
water). The reaction was carried out overnight at 4 °C. Free DNA was removed by size 
exclusion chromatography (SEC) eluted with PBS. 
 
Preparation of HRP-Ncomp: PDMS22-PMOXA8-OEG3-N3 stock solution (200 µL, 10 mg/mL) 
was transferred into a 5 mL round-bottomed flask, and dried on a rotary evaporator (170 mbar, 
40 ˚C, 75 rpm). HRP solution (100 μL, 0.2 mg/mL) containing 0.1 wt% BSA with either PBS 
(100 µL) or OmpF (100 μL, 0.1 mg/mL or 0.2 mg/mL) was added to the residue, resulting in a 
final concentration of 0.16 mg/mL of HRP, 4 mg/mL of PDMS22-PMOXA8-OEG3-N3 and 0 
mg/mL, 0.02 mg/mL, and 0.04 mg/mL of OmpF. The flask was gently shaken with a stirring 
bar for less than 10 seconds at room temperature. The resultant HRP-Ncomp was extruded the 
same way as described for the empty polymersomes. Free HRP was removed by means of SEC, 
eluted with PBS.  
 
Activity of HRP-Ncomp: HRP-Ncomp (10 μg/mL) was incubated in the presence of H2O2 (10 
µM) in a 96-well black plate (Thermo Fisher Scientific), before the addition of Amplex Red (1 
µM) to give a final volume of 200 µL/well. The change of fluorescence (excitation 570 nm / 
emission 595 nm) after the addition of Amplex Red was recorded immediately using a 





Preparation of DDC-Ncomp:A solution of PDMS22-PMOXA8-OEG3-N3 polymer dissolved in 
ethanol (600 µL, 10 mg/mL) was transferred into a 5 mL round-bottomed flask, and dried on a 
rotary evaporator (170 mbar, 40 ˚C, 75 rpm). In parallel, freshly thawed DDC (20 µg) was 
dissolved in 0.1 wt% BSA in PBS (1 mL) and pyridoxal phosphate in PBS (50 µL, 5 mM). The 
mixture was gently stirred at 4°C for 20 min. The thin polymer film was rehydrated with this 
DDC solution (522 µL) mixed with dialyzed OmpF solution (78 µL, 0.8 mg/mL to give the 
same polymer/OmpF ratio as used for HRP-Ncomp) (see the SI for further details). The 
resulting solution was stirred 3 hours at 4 °C, and then extruded 15 times through a PC 
membrane with a 200 nm diameter pore size under sterile conditions to unify the size of the 
polymersomes.  
 
DDC encapsulation efficiency: Polymersomes encapsulating BSA (BSA-Ncomp) were formed 
under the same conditions described above, but using BSA in place of DDC and using PBS 
only (without further 0.1wt% BSA). The concentration of non-encapsulated BSA was 
determined from the fraction of free BSA present in the solution after SEC purification of BSA-
Ncomp. Polymersomes rehydrated under the same conditions but without BSA were also 
formed and purified for use as a blank. After UV-vis (280 nm) absorbance measurements using 
a NanoDrop 2000 spectrophotometer (Thermofisher) in BSA mode, we determined the amount 
of BSA molecules encapsulated in polymersomes. We calculated the difference between the 
total amount of BSA used for film rehydration and the amount of non-encapsulated BSA, which 
gave a number of 1.79*1013 ± 4.71*1012 molecules of BSA encapsulated. In parallel, the 
concentration of vesicles (1.3*1012 vesicles/mL) was determined via single nanoparticle 




(Malvern, United Kingdom). We divided the number of encapsulated BSA molecules by the 
number of vesicles in our solution (600 µL), obtaining a value of 23.01 ± 6.03 BSA molecules 
encapsulated per vesicle. Assuming similar numbers of BSA and DDC, the percentage of DDC 
encapsulation is calculated to be 15.6 ± 4.12 %. 
 
OmpF expression and extraction: Wild-type OmpF was obtained according to a previously 
reported protocol,[53] with a few modifications: bacteria were grown at 30 °C for 6 h on Terrific 
Broth (TB) (Difco, U.S.A.), and all ultracentrifugations were performed at room temperature. 
 
Preparation of Dye-Ncomp: A stock solution of PDMS22-PMOXA8-OEG3-N3 block copolymer 
was obtained by dissolution of the polymer in ethanol (600 µL, 10 mg/mL), and transferred to 
a round-bottomed flask, followed by drying on a rotary evaporator (170 mbar, 40 ˚C, 75 rpm). 
The resultant thin polymer film was rehydrated by adding a solution of DY-633 (600 µL, 0.2 
mM in PBS). The product was stirred overnight at room temperature before being extruded in 
the same way as described for DDC-Ncomp.  
 
DNA conjugation and cluster formation: Extruded DDC-Ncomp and Dye-Ncomp (500 µL 
each) were mixed with 1 eq. per azide group of ssDNA/spacer-ssDNAa (0.5 mM in water) 
overnight (4 °C) and ssDNAb/spacer-ssDNAb (0.5 mM in water) overnight (37 °C), 
respectively. The two solutions were purified by means of SEC to remove free DNA, under 
sterile conditions, and cold PBS. The volumes of purified polymersomes solutions were 
adjusted to obtain a polymer concentration of 2 mg/mL. To prepare clusters, the two solutions 






Transmission electron microscopy (TEM): A 5 μL aliquot of polymersomes or polymersome 
clusters (0.1 mg/mL) was absorbed on 400 mesh square copper grids. The grids were further 
stained with 2% uranyl acetate and the negatively stained image of nanostructures was obtained 
with a transmission electron microscope (Philips CM100) at an accelerating voltage of 80 kV.  
Dynamic light scattering (DLS): The apparent DH values of polymersomes and polymersome 
clusters were obtained on a Zetasizer Nano ZSP (Malvern Instruments Inc., UK) at 25 °C. 400 
μL of each sample solution (0.2 mg/mL final concentration) was added to a cuvette and 
subjected to 11 runs repeated three times. The measured angle was 173° and the data was 
analyzed by number distribution. To examine the kinetics of polymersome cluster formation, 
measurements were run for 3 min with a 2 min interval.  
Zeta potential measurement: The electrophoretic mobility of vesicles in solution was 
determined by means of laser Doppler velocimetry and phase-analysis light-scattering 
measurements. A Malvern Zetasizer Nano ZSP (Malvern Instruments Inc, UK) with a 633 nm 
wavelength laser was used for all measurements. The vesicle samples (0.2 mg/mL) were 
measured in PBS with five repeat measurements per sample. All experiments were run at 25 °C. 
Static light scattering (SLS): Multi-angle dynamic light scattering (DLS) and static light 
scattering (SLS) were performed on a setup from LS Instruments (Switzerland), equipped with 
a 21 mW He-Ne laser (λ = 632.8 nm) for scattering angles from 30° to 150° at 25 °C. All 
samples were diluted in order to suppress multiple scattering. Second-order cumulant analysis 
for various angles was performed to obtain the hydrodynamic radius (Rh). The radius of 





Fluorescence Correlation Spectroscopy (FCS): FCS was performed on a Zeiss LSM 880 
microscope (Zeiss LSM 880, inverted microscope ZEISS Axio Observer, Carl Zeiss, Jena, 
Germany). A 488 nm argon laser was used to excite ssDNA labelled with Atto-488 and the 
conjugated Ncomp. The laser beam was passed through main beam splitter MBS488 and signals 
were detected in the range of 500-532 nm. A 633 nm HeNe laser, was used for DY-633 labelled 
ssDNA and the conjugated Ncomp. The laser beam was passed through MBS488/561/633 filter 
and the signal was detected in the range of 650-740 nm, the pinholes were adjusted to maximize 
the count rate using the corresponding free dye in PBS. The sample volume was 15 μL. 
Fluorescence fluctuations over time were recorded for 30 x 10 s. The raw data was processed 
and analyzed using Zeiss software. Autocorrelation curves were fitted to a two-component 
model (Equation S1).  



























1/2]    (1) 
Where 𝐺2𝑐𝑜𝑚𝑝(𝜏)  is the two-component autocorrelation function, N is the number of 
particles, S is the structural parameter, 𝑇𝑡𝑟𝑖𝑝 is the fraction of fluorophores in the triplet state, 
𝜏𝑡𝑟𝑖𝑝  is the corresponding triplet time, f1 and f2 are the fractions of the particles of the 
corresponding component 1 or 2, and 𝜏𝐷1 and 𝜏𝐷2 are the diffusion times of the corresponding 
component 1 or 2. 
Confocal laser scanning microscopy (CLSM): CLSM measurements were recorded on a 
confocal laser-scanning microscope (ZEISS LSM 880, inverted microscope ZEISS Axio 
Observer, Carl Zeiss, Germany). For visualizing polymersome clusters in the presence of cells, 




nm argon laser and a 633 nm HeNe laser, were used. The beams were passed through MBS488 
and MBS488/561/633 filters, respectively, and focused onto the sample through a water 
immersion objective (C-Apochromate 40x/1.2W korr FCS M27). Detection was done at 505-
555 nm and 650-740 nm, respectively. For polymersome clusters formed from DDC-Ncomp 
and dye-Ncomp, only the 633 nm HeNe laser was utilized.  
Activity determination of the therapeutic compartment: 80 µL of purified 1 mg/mL of DDC-
Ncomp, DDC-Ncomp functionalized with ssDNA, theragnostic clusters or DDC-Ncomp 
without OmpF was mixed with 10 µL of L-dopa (5 mM in water), 10 µL of reduced glutathione 
(20 mM in PBS) and 2 µL of pyridoxal phosphate (5 mM in water), and incubated 24 h at 37 °C. 
Then, each solution was purified by SEC to remove the polymersomes, and analysed by reverse-
phase HPLC to detect the presence of dopamine. The percentage conversion of L-Dopa to 
dopamine was calculated from the areas of the corresponding peaks: for every sample, the area 
of the dopamine peak is multiplied by 100 and divided by the sum of the areas of the dopamine 
and L-Dopa peaks. This approach was chosen to avoid potential errors in the assessment of L-
Dopa and dopamine concentrations due to sample dilution during SEC purification, which was 
required to prevent injection of vesicles into the HPLC.  
 
HPLC: The retention times for dopamine and L-Dopa were determined using a reverse-phase 
Shimadzu HPLC (Reinach, Switzerland). A 20-min method using water containing 0.1% TFA 
as a mobile phase at 0.5 mL/min though an analytical Chromolith performance RP-18e column 
(Merck, Schaffhausen, Switzerland) separated dopamine (10.1 min) and L-Dopa (11.8 min) 
(Figure S7). At equal concentrations, the peaks corresponding to dopamine and L-Dopa showed 





Cell culture: The stable double-transgenic cell line HEKREWARD was cultured in Dulbecco’s 
modified Eagle’s medium GlutaMAXTM-I (DMEM-GlutaMAX, Gibco Life Sciences) 
supplemented with 10% FCS (BioConcept), 100 units/mL penicillin and 100 µg/mL 
streptomycin (Sigma Aldrich). After 14 days, the polyclonal population was selected according 
to reported methodology.[47] Cells were maintained at 37 ºC in a humidified atmosphere of 5% 
CO2 in air.  
 
Cellular attachment and imaging: Freshly trypsinized cells were seeded at a density of 60 000 
cells per well, in 8-well ibidi collagen IV-coated plates. After 24 h, the cell culture medium was 
removed and replaced with 130 µL Opti-MEM (Gibco Life Sciences) live cell imaging medium. 
Next, cells were dosed with polymersome clusters (70 µL, 2 mg/mL) and imaged by CLSM at 
intervals for 2 h. CLSM measurements were performed on a ZEISS LSM 880 inverted 
microscope (ZEISS Axio Observer, Carl Zeiss, Germany) with a water immersion objective C-
Apochromate 40x/1.2W korr FCS M27. For Atto-488, the beam from a 488 nm argon laser was 
passed through a main beam splitter MBS488; detection was done at 499-643 nm. For DY-633, 
the HeNe 633 nm laser beam was passed through MBS488/561/633 filters and detection was 
done at 638-759 nm. 
For the 24 hour time points, freshly trypsinized cells were seeded at a density of 30 000 cells 
per well in 8-well ibidi collagen IV-coated plates. After 24 h, cells were treated with the 
polymersome clusters as previously described. After a further 24 h incubation, the cells were 
washed 3x with Opti-MEM prior to CLSM imaging. Images were processed using Fiji ImageJ 
and colocalization analysis based on Pearson’s coefficient of colocalization was performed 





Cell activation by DDC-Ncomp and theragnotic clusters: Cells were plated in a 96-well plate 
(100 µL/well of 10 000 cells) and incubated overnight. The next day, 75 µL of media was 
removed and 75 µL of free DDC (different concentrations) or 1 mg/mL of DDC-Ncomp w/o 
OmpF, DDC-Ncomp, ssDNA-functionalized DDC-Ncomp or theragnostic clusters was added 
to the wells. Wells were filled with 100 µL of media containing L-dopa (10 µM) and pyridoxal 
phosphate (12.5 µM) and incubated for 3 days. Then, the SEAP level was assayed using a 
standard p-nitrophenyl phosphate–based absorbance method as previously described.[70] In 
brief, the cell supernatant corresponding to each condition was assayed by recording the rate of 
production of p-nitrophenol from the SEAP substrate p-nitrophenyl phosphate, calculated from 
the absorbance at 405 nm. The amount of SEAP expressed under each condition was calculated 
using the slope of the kinetic curve of p-nitrophenol production. 
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Figure 1. Schematic illustration of cell attachment of DNA-zipped theranostic polymersome 
clusters composed of two distinct compartments: therapeutic DDC-Ncomp and imaging Dye-
Ncomp. While Dye-Ncomp contains fluorescent DY-633 dye, DDC-Ncomp contains DDC, 
which catalyzes the conversion of L-Dopa into dopamine. This in turn triggers gene expression 






Figure 2. Design of DNA-zipped theragnostic polymersome clusters: A) Schematic 
representation of the formation of DDC-Ncomp linked with spacer-ssDNAa; B) Schematic 
representation of the formation of Dye-Ncomp linked with spacer-ssDNAb; C) Average 
numbers of ssDNA (solid) and spacer-ssDNA (stripped) linked to DDC-Ncomp (orange) and 




spacer-ssDNAa (left) and Dye-Ncomp linked with spacer-ssDNAb (right); E) Average apparent 
diameter of DDC-Ncomp linked with spacer-ssDNAa (orange) and Dye-Ncomp (pink) linked 
with spacer-ssDNAb; F) Schematic representation of the formation of theranostic cluster 
constituted by DDC-Ncomp and Dye-Ncomp linked together via hybridization of their 
complementary spacer-ssDNA; G) The change of apparent size of theranostic clusters DDC- 
linked by ssDNA (green) and spacer-ssDNA (blue) as a function of time; H) TEM micrograph 
of polymersome clusters (scale bar is 500 nm); I) Average apparent diameters of DDC-Ncomp 










Figure 3. A) HPLC chromatograms showing elution peaks corresponding to dopamine 
(retention time 10.1 min) and L-Dopa (retention time 11.8 min) for free DDC in PBS (grey), 
free DDC in the presence of BSA (black), DDC-encapsulating polymersomes (DDC-Ncomp, 
orange), DDC-Ncomp theranostic clusters (blue), ssDNA-functionalized DDC-Ncomp (green) 
and control DDC-Ncomp without OmpF (purple), after reaction for 24 h at 37 °C. B) Processed 
HPLC data showing the percent conversion of L-Dopa to dopamine by the different DDC-
containing samples and assemblies, illustrating the kinetics of these systems up to 24 h at 37 °C 




PBS. D) Processed HPLC data showing the stability of these systems up to 24 h at 4 °C in PBS. 
Full conversion (100% conversion) equates to a concentration of 490 µM dopamine. 
 
 
Figure 4. A) Absorbance-monitoring of the enzymatic production of chromogenic p-
nitrophenol from SEAP substrate p-nitrophenyl phosphate in the cell supernatant, to assess 
cellular production of SEAP induced by different concentrations of free DDC (0.001 µg/mL to 
1 µg/mL) in the presence of 0.1 wt% of BSA. B) Cell expression of SEAP (U/L) induced by 
different concentrations of free DDC (with BSA) after 3 days. C) Comparison of cellular 
production of SEAP (U/L) induced by DDC-encapsulating polymersomes or free DDC in BSA, 
at 0.1 µg/mL or 0.05 µg/mL DDC concentration. D) Cell expression of SEAP (U/L) induced 




encapsulating polymersomes (orange), DDC-Ncomp theragnostic clusters (blue), control DDC-
Ncomp without OmpF(purple), L-Dopa (grey) and PBS only (black). 
 
 
Figure 5. CLSM micrographs from four different locations of 488-633-Ncomp clusters 




and Atto-488 channels, transmission channel and merged images (scale bar = 40 μm). B) 
Merged DY-633 and Atto-488 channels of the four locations with colocalized regions appearing 
in white. Colocalization analysis of the four locations resulted in a Pearson’s coefficient of 0.77 

























We have developed nanocompartment cluster-based nanotheranostics implementing activation 
of cell-membrane receptors. Polymersome clusters segregate Dopa decarboxylase (DDC) and 
fluorescence probes into distinct compartments. The compartment hosting DDC enables 
conversion of L-Dopa to dopamine, which interacts with human dopamine receptor 1 to induce 
a cellular response. The compartment loaded with dye allows spatiotemporal monitoring of the 
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